<DOC>
	<DOCNO>NCT02259751</DOCNO>
	<brief_summary>Study investigate pharmacodynamic effect pharmacokinetics KUC 7483</brief_summary>
	<brief_title>Study Determine Pharmacodynamic Effects Pharmacokinetics KUC 7483 CL Patients With Spinal Cord Injury Neurogenic Detrusor Overactivity</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>p-Hydroxyamphetamine</mesh_term>
	<criteria>1 . Male patient acquire suprasacral spinal cord injury practice intermittent catheterization stable condition determine investigator 2 . Recovery spinal shock posttraumatic patient 3 . Aged 18 70 year 4 . BMI range ≥ 18.5 &lt; 29.9 kg/m2 5 . Documented neurogenic detrusor overactivity show urodynamics within last 12 month prior study start confirmation baseline urodynamics ( day 2 ) . Detrusor overactivity define nonvolitional increase detrusor pressure &gt; 6 cm H2O . Detrusor sphincter dyssynergia may facultative 6 . Written inform consent consistent International committee harmonization ( ICH ) / Good Clinical Practice ( GCP ) local legislation give prior study procedure 7 . Ability willingness comply study treatment regimen attend study 1 . A total daily volume urine &gt; 3000 ml verify micturition diary randomization 2 . Treatment drug know anticholinergic effect detrusor and/or alphablockers , 7 day prior inclusion visit 2 3 . Treatment botulinus toxin , capsaicin resiniferatoxin last 6 month prior study 4 . Unstable dosage drug expectation initiation treatment trial 5 . Use agonists antagonist betaadrenoceptors ( The follow drug may nevertheless use since act upon beta3 adrenoceptors therapeutic dos : atenolol , bisoprolol , carvedilol , metoprolol , propranolol , salbutamol salmeterol ) 6 . Neurological disease suprasacral spinal cord injury , affect urinary bladder function 7 . Significant stress incontinence determine investigator 8 . Nonfunctional bladder outlet obstruction determine investigator 9 . Dilatation upper urinary tract 10 . Low compliance bladder ( Compliance &lt; 20 mL/cm H2O ) 11 . Detrusor hyporeflexia/areflexia bradykinesia/tremor external urethral sphincter 12 . Prostatic bladder carcinoma 13 . Acute urinary tract infection runin period study period 14 . History interstitial cystitis 15 . Surgery prostate , urinary bladder , urethra , thermotherapy , ultrasound laser therapy prostate 12 month prior enrolment study 16 . Pelvic radiation therapy 17 . Use indwelling catheter 18 . Any electro stimulation therapy within 14 day prior inclusion visit 2 19 . Significant hepatic renal disease define twice upper limit reference range , regard serum concentration Aspartate transaminase ( ( SGOT ) ( AST ) ) , Alanine transaminase ( ( SGPT ) ALT ) ) , Alkaline phosphatase ( ALP ) , and/or creatinine &gt; 1.4 mg/dl 20 . Diseases condition , treatment ß3adrenoceptors agonist contraindicate 21 . Participation another clinical trail 8 week precede enrolment study study period 22 . Patients severe medical condition opinion investigator make patient unsuitable inclusion 23 . Allergic KUC7483 excipients 24 . Patients Diabetes mellitus type 1 2 treated oral antidiabetic drug insulin ( formulation )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>